International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	GUT MICROBIOTA AS A KEY MODULATOR OF METABOLIC SYNDROME AND OBESITY: MECHANISMS, CLINICAL EVIDENCE, AND THERAPEUTIC PERSPECTIVES
DOI	https://doi.org/10.31435/ijitss.2(50).2026.5108
RECEIVED	02 February 2026
ACCEPTED	25 May 2026
PUBLISHED	11 June 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

GUT MICROBIOTA AS A KEY MODULATOR OF METABOLIC SYNDROME AND OBESITY: MECHANISMS, CLINICAL EVIDENCE, AND THERAPEUTIC PERSPECTIVES

Karolina Wymoczył *(Corresponding Author, Email: karolina.gordi@gmail.com)*
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
ORCID ID: 0009-0004-7326-8013

Natalia Cieślak
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0004-6355-8164

Agata Chodkowska
Medical University of Lublin, Lublin, Poland
ORCID ID: 0009-0000-5006-3040

Aleksandra Cyrkler
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
ORCID ID: 0009-0001-6865-7450

Kamila Czyżak
John Paul II Municipal Hospital in Rzeszów, Rzeszów, Poland
ORCID ID: 0000-0002-8866-5810

Urszula Marzec
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
ORCID ID: 0009-0000-6348-184X

Karol Dąbek
John Paul II Municipal Hospital in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0005-6152-3870

Eliza Rajca
Wojewódzki Szpital Zespolony, Kielce, Poland
ORCID ID: 0009-0005-6024-4298

Agnieszka Giza
Independent Public Hospital No. 4 in Lublin, Lublin, Poland
ORCID ID: 0009-0002-5741-3482

Paulina Giza
Medical University of Warsaw, Warsaw, Poland
ORCID ID: 0009-0004-7637-5906

ABSTRACT

The global escalation of obesity and metabolic syndrome (MetS) represents a significant challenge to public health systems (World Health Organization, 2024). Emerging evidence identifies the gut microbiota—the complex community of microorganisms inhabiting the gastrointestinal tract—as a critical environmental factor influencing host energy homeostasis and inflammation (Evans et al., 2013). This review examines the intricate mechanisms through which gut dysbiosis contributes to the pathogenesis of obesity and MetS, including altered energy extraction, modulation of lipid metabolism, and the induction of chronic low-grade inflammation via metabolic endotoxemia (Cani et al., 2007). We synthesize current clinical evidence from human cohort studies that correlate specific microbial signatures with metabolic health (Le Chatelier et al., 2013). Furthermore, this article explores therapeutic perspectives, evaluating the efficacy of probiotics, prebiotics, and fecal microbiota transplantation (FMT) in restoring metabolic balance (Vrieze et al., 2012). A core focus is placed on the integration of advanced bioinformatic frameworks, such as the QIIME 2 pipeline and Random Forest machine learning architectures, which facilitate the transition from taxonomic description to functional, predictive modeling of the gut-metabolic axis (Knight et al., 2018; Zeevi et al., 2015). By integrating findings from molecular biology, systems engineering, and clinical trials, we conclude that the gut microbiota is a viable target for personalized therapeutic interventions in metabolic diseases (Fan & Pedersen, 2021).

KEYWORDS

Gut Microbiota, Obesity, Metabolic Syndrome, Dysbiosis, Short-Chain Fatty Acids, Inflammation

CITATION

Karolina Wymoczył, Natalia Cieślak, Agata Chodkowska, Aleksandra Cyrkler, Kamila Czyżak, Urszula Marzec, Karol Dąbek, Eliza Rajca, Agnieszka Giza, Paulina Giza. (2026) Gut Microbiota as a Key Modulator of Metabolic Syndrome and Obesity: Mechanisms, Clinical Evidence, and Therapeutic Perspectives. *International Journal of Innovative Technologies in Social Science*. 2(50). doi: 10.31435/ijitss.2(50).2026.5108

1. Introduction

The global prevalence of obesity has nearly tripled since 1975, creating a pandemic of non-communicable diseases (World Health Organization, 2024). Metabolic Syndrome (MetS) is no longer viewed merely as a consequence of caloric surfeit but as a complex systemic failure of homeostatic regulation (Alberti et al., 2009). Emerging paradigms suggest that the trillions of microbes residing in the human gastrointestinal tract, collectively known as the gut microbiota, function as a dynamic endocrine organ (Evans et al., 2013). These microbes orchestrate host metabolism by fermenting complex polysaccharides, modulating the immune system, and influencing the gut-brain axis (Cryan & Dinan, 2012).

Recent metagenomic studies have identified that individuals with low microbial gene richness are more prone to weight gain and chronic inflammation (Le Chatelier et al., 2013). This review aims to dissect the molecular mechanisms—ranging from Short-Chain Fatty Acid (SCFA) signalling to metabolic endotoxemia—that link dysbiosis to metabolic dysfunction. Furthermore, it evaluates the clinical transition of microbiota-based therapies from animal models to bedside applications in humans (Turnbaugh et al., 2009).

2. Methodology

To provide a comprehensive overview, a systematic search was conducted across PubMed, Scopus, and Web of Science databases for articles published between 2010 and 2025. Search terms included "gut microbiota," "obesity," "metabolic syndrome," "short-chain fatty acids," and "therapeutic interventions."

A total of 150 primary sources were initially screened, with 50 key publications selected for final synthesis based on their impact factor and longitudinal data quality.

Inclusion Criteria:

- Peer-reviewed original research and meta-analyses.
- Human clinical trials and mechanistic animal studies.
- Articles focused specifically on the modulation of metabolic pathways by gut bacteria.

The literature was synthesized to identify common microbial patterns and mechanistic pathways, ensuring a balanced view of current scientific consensus and emerging controversies.

3. Mechanisms of Microbiota-Induced Metabolic Change

3.1 Detailed Biochemical Signalling of Short-Chain Fatty Acids (SCFAs)

The fermentation of complex carbohydrates—specifically resistant starches, inulin, and non-starch polysaccharides—by anaerobic gut bacteria represents a cornerstone of the symbiotic relationship between humans and their microbiota (Macfarlane & Macfarlane, 2011). The resulting SCFAs (acetate, propionate, and butyrate) are not merely metabolic byproducts; they are high-affinity ligands for specific G protein-coupled receptors (GPCRs), namely GPR41 (Free Fatty Acid Receptor 3, FFAR3), GPR43 (Free Fatty Acid Receptor 2, FFAR2), and GPR109A (HCAR2) (Brown et al., 2003).

3.1.1 The Role of GPR43 (FFAR2) in Lipid Homeostasis

GPR43 is predominantly expressed in the ileum, colon, and, crucially, in white adipose tissue (Kimura et al., 2013). When acetate and propionate bind to GPR43 in adipocytes, they trigger a signalling cascade that inhibits lipolysis and promotes the differentiation of pre-adipocytes into mature adipocytes (Ge et al., 2008). While this might seem counterintuitive in the context of obesity, GPR43-mediated adipogenesis actually promotes the formation of "metabolically healthy" small adipocytes, which are more insulin-sensitive than the hypertrophic adipocytes found in metabolic syndrome (Bjursell et al., 2011). Furthermore, GPR43 activation in the gut stimulates the release of Peptide YY (PYY) and Glucagon-like Peptide-1 (GLP-1), which act on the hypothalamus to induce satiety and improve peripheral glucose disposal (Tolhurst et al., 2012).

3.1.2 GPR41 (FFAR3) and Energy Expenditure

GPR41 is highly expressed in the sympathetic nervous system and enteric neurons (Samuel et al., 2008). Unlike GPR43, activation of GPR41 by propionate and butyrate has been shown to increase sympathetic outflow, thereby raising the basal metabolic rate and body temperature (Kimura et al., 2011). In murine models, GPR41-deficient mice exhibit significantly lower energy expenditure and are more prone to obesity compared to wild-type mice, even when consuming the same diet (Samuel et al., 2008). This suggests that a lack of specific SCFA-producing bacteria leads to a "thrifty" metabolic state where energy is stored rather than burned.

3.1.3 The "Thrifty Gene" Evolution Theory

The "energy harvest" capacity of the gut microbiota must be viewed through an evolutionary lens, specifically the "thrifty gene" hypothesis (Backhed et al., 2004). Throughout human history, periods of nutritional scarcity were the norm rather than the exception. It is hypothesized that the human gut microbiota evolved to maximize the extraction of calories from fibrous, low-energy diets thereby ensuring host survival during famine (Turnbaugh et al., 2006). In this symbiotic framework, certain microbial phyla, such as *Firmicutes*, developed highly efficient metabolic pathways to ferment complex polysaccharides into absorbable energy (Backhed et al., 2004). However, in the modern "obesogenic" environment characterized by a constant surplus of high-calorie, low-fiber foods, this once-beneficial trait has become maladaptive. The microbial ecosystem, still programmed for maximum energy retention, continues to extract and deliver excess calories to a host that is already in a state of caloric surfeit, thereby accelerating the development of obesity and metabolic syndrome (Turnbaugh et al., 2009). This evolutionary mismatch underscores the difficulty of managing obesity through diet alone, as the microbial "thrifty" mechanism operates independently of the host's conscious caloric restriction (Backhed et al., 2004).

3.1.3 Butyrate, GPR109A, and Epigenetic Modulation

Butyrate serves a dual role: it is a primary ligand for GPR109A and a potent inhibitor of Histone Deacetylases (HDACs) (Zimmerman, 2012). By inhibiting HDACs, butyrate promotes the acetylation of histones in the promoter regions of anti-inflammatory genes, such as *FOXP3*, which is essential for the differentiation of regulatory T-cells (Tregs) (Furusawa et al., 2013). This epigenetic modulation directly dampens the chronic low-grade inflammation associated with obesity (Smith et al., 2013). Furthermore, butyrate activation of GPR109A in the colonic epithelium strengthens the mucosal barrier by inducing the expression of antimicrobial peptides and tight-junction proteins, thereby reducing the translocation of pro-inflammatory LPS (Singh et al., 2014).

3.1.4 Propionate and Intestinal Gluconeogenesis (IGN)

One of the most profound discoveries in recent years is the ability of propionate to stimulate intestinal gluconeogenesis (IGN) (De Vadder et al., 2014). Unlike hepatic gluconeogenesis, which raises blood sugar, IGN sends a signal through the portal vein to the brain, which then triggers a reduction in hepatic glucose production and an increase in insulin sensitivity (De Vadder et al., 2016). This gut-brain-liver axis explains why high-fiber diets are so effective at controlling hyperglycaemia in patients with Type 2 Diabetes (Zhao et al., 2018).

3.2 Metabolic Endotoxemia & Leaky Gut: The Role of Intestinal Permeability and LPS

The transition from a healthy metabolic state to one characterized by insulin resistance and chronic low-grade inflammation is often mediated by the "leaky gut" phenomenon (Cani et al., 2008). In a healthy individual, the intestinal epithelium acts as a highly selective barrier, maintained by a complex network of tight-junction (TJ) proteins, including claudins, occludin, and zonula occludens-1 (ZO-1) (Groschwitz & Hogan, 2009). However, prolonged consumption of a Western-style diet—high in saturated fats and refined sugars—induces a state of intestinal dysbiosis that actively undermines this structural integrity (Cani et al., 2007).

3.2.1 Mechanisms of Barrier Disruption

The disruption of the gut barrier is primarily driven by a decrease in the abundance of mucin-degrading bacteria that maintain the protective mucus layer, such as *Akkermansia muciniphila*, and a concomitant increase in opportunistic pathogens (Everard et al., 2013). High fat intake increases the production of bile acids, which can have a detergent-like effect on the intestinal membrane, further increasing permeability (Stenman et al., 2012). As the tight junctions weaken, the paracellular pathway becomes compromised, allowing the translocation of pro-inflammatory molecules from the lumen into the portal circulation (Muccioli et al., 2010).

3.2.2 Lipopolysaccharide (LPS) as a Trigger for Systemic Inflammation

The most critical molecule in this process is Lipopolysaccharide (LPS), an endotoxin found in the outer membrane of Gram-negative bacteria (Cani et al., 2007). Under normal conditions, trace amounts of LPS enter the bloodstream via chylomicrons during fat absorption (Ghoshal et al., 2009). However, in the context of metabolic syndrome, the systemic concentration of LPS increases twofold to threefold—a condition termed "metabolic endotoxemia" (Cani et al., 2007).

Unlike the acute, high-level endotoxemia seen in septic shock, metabolic endotoxemia is a chronic, low-level stimulus that keeps the innate immune system in a state of constant activation (Pussinen et al., 2011). Once in the blood, LPS binds to Lipopolysaccharide-Binding Protein (LBP) and is delivered to the CD14/Toll-Like Receptor 4 (TLR4) complex on the surface of macrophages and adipocytes (Shi et al., 2006).

3.2.3 The TLR4 Signaling Cascade and Insulin Resistance

Activation of TLR4 by LPS initiates an intracellular signalling cascade involving the adaptor protein MyD88, which leads to the activation of Nuclear Factor-kappa B (NF-κB) and C-Jun N-terminal Kinase (JNK) (Shi et al., 2006). These pathways stimulate the production and release of pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6) (Hotamisligil, 2006).

The impact of this chronic inflammation on insulin sensitivity is profound. TNF-α and IL-6 promote the serine phosphorylation of Insulin Receptor Substrate-1 (IRS-1), which effectively blocks the normal tyrosine phosphorylation required for insulin signalling (Hotamisligil et al., 1996). Consequently, the GLUT4 glucose transporters are not translocated to the cell membrane, leading to hyperglycaemia and compensatory hyperinsulinemia (Shi et al., 2006). This mechanism establishes a direct molecular link between gut-derived endotoxins and the development of Type 2 Diabetes (T2D).

3.2.4 Adipose Tissue Dysfunction and Macrophage Infiltration

Metabolic endotoxemia also fundamentally alters the biology of adipose tissue. In response to LPS and circulating cytokines, white adipose tissue (WAT) undergoes significant remodelling, characterized by the infiltration of M1-polarized (pro-inflammatory) macrophages (Xu et al., 2003). These macrophages form "crown-like structures" around necrotic adipocytes, creating a localized inflammatory environment that further drives systemic insulin resistance (Weisberg et al., 2003). The microbiota thus serves as the "upstream" trigger for "downstream" adipose tissue inflammation (Cani & Jordan, 2018).

3.3 The Bile Acid-Microbiota Axis and Metabolic Signalling

Bile acids (BAs) are synthesized from cholesterol in the liver and secreted into the duodenum to facilitate the emulsification and absorption of dietary lipids and fat-soluble vitamins (Chow et al., 2017). However, research over the last decade has repositioned BAs as complex metabolic hormones that regulate glucose, lipid, and energy homeostasis through the activation of nuclear and G protein-coupled receptors (Sayin et al., 2013). The gut microbiota is the primary architect of the bile acid pool, performing critical transformations—including deconjugation, dehydroxylation, and epimerization—that alter the signalling properties of these molecules (Wahlström et al., 2016).

3.3.1 Microbial Transformation of Bile Acids

The initial step in microbial BA metabolism is the hydrolysis of the C-24 amide bond by Bile Salt Hydrolases (BSH), enzymes produced by various genera including *Lactobacillus*, *Bifidobacterium*, and *Bacteroides* (Jones et al., 2008). This deconjugation process prevents the reabsorption of BAs in the small intestine, leading to their excretion or further transformation in the colon. Following deconjugation, certain species, particularly from the *Clostridium* clusters XIVa and IV, perform 7α-dehydroxylation, converting primary BAs (Cholic Acid and Chenodeoxycholic Acid) into secondary BAs (Deoxycholic Acid and Lithocholic Acid) (Ridlon et al., 2006). This conversion is metabolically significant because secondary BAs have a higher affinity for the TGR5 receptor than primary BAs (Thomas et al., 2009).

3.3.2 TGR5 Signalling and Energy Expenditure

TGR5 (Takeda G Protein-Coupled Receptor 5) is widely expressed in the gallbladder, intestinal L-cells, and brown adipose tissue (BAT) (Maruyama et al., 2002). Activation of TGR5 by microbially-produced secondary BAs in the ileum stimulates the secretion of Glucagon-Like Peptide-1 (GLP-1), a potent incretin hormone that enhances glucose-dependent insulin secretion and inhibits glucagon release (Thomas et al., 2009). Furthermore, in BAT, TGR5 signalling increases the activity of the enzyme type 2 iodothyronine deiodinase (D2), which converts inactive thyroid hormone (T4) into active T3 (Watanabe et al., 2006). This intracellular thyroid activation increases mitochondrial oxidative phosphorylation and thermogenesis, effectively increasing the host's basal metabolic rate and protecting against diet-induced obesity (Broeders et al., 2015).

3.3.3 The FXR Axis and Hepatic Metabolism

The metabolic influence of the gut microbiota is perhaps most profoundly seen in its ability to chemically modify bile acids, transforming them from simple detergents into complex endocrine ligands (Fogelson et al., 2024). When primary bile acids, such as cholic acid (CA) and chenodeoxycholic acid (CDCA), enter the large intestine, they encounter bacterial enzymes, primarily bile salt hydrolases (BSH), which catalyse the deconjugation of glycine or taurine groups (Jones et al., 2008). This is followed by 7α/β-dehydroxylation, a process predominantly carried out by a limited number of species within the *Clostridiaceae* family, resulting in the formation of secondary bile acids like deoxycholic acid (DCA) and lithocholic acid (LCA) (Ridlon et al., 2006).

This microbial "editing" of the bile acid pool is critical because it dictates the activation threshold of the Takeda G protein-coupled receptor 5 (TGR5). Secondary bile acids, specifically LCA, exhibit a significantly higher affinity for TGR5 compared to their primary counterparts (Thomas et al., 2009). Once activated in the intestinal L-cells, TGR5 triggers an intracellular increase in cyclic adenosine monophosphate (cAMP), which stimulates the proglucagon gene expression and the subsequent release of Glucagon-like peptide-1 (GLP-1) (Thomas et al., 2009). This incretin effect is essential for postprandial insulin secretion and the regulation of gastric emptying, providing a direct microbial link to glycaemic control in patients with metabolic syndrome (Vrieze et al., 2012). Furthermore, in brown adipose tissue (BAT), the TGR5-cAMP pathway induces the enzyme type 2 iodothyronine deiodinase (D2), which facilitates the conversion of thyroxine (T4) to the metabolically active triiodothyronine (T3) (Watanabe et al., 2006). This intracellular thyroid activation promotes thermogenesis by uncoupling mitochondrial respiration through UCP1, thereby increasing energy expenditure and mitigating the storage of triglycerides in white adipose tissue (Broeders et al., 2015).

Parallel to the TGR5 pathway is the Farnesoid X Receptor (FXR) axis. FXR serves as a nuclear receptor that senses the abundance of primary bile acids (Makishima et al., 1999). Upon activation in the ileum, FXR stimulates the secretion of Fibroblast Growth Factor 19 (FGF19), which enters the portal circulation and signals the liver to suppress *de novo* bile acid synthesis via the inhibition of the CYP7A1 enzyme (Inagaki et al., 2005). In the context of obesity, a state of dysbiosis often leads to an overgrowth of bacteria that produce FXR antagonists, such as tauro-beta-muricholic acid, which effectively "blinds" the host to its bile acid levels (Sayin et al., 2013). This disruption results in a failure of the FGF15/19 feedback loop, leading to an unregulated bile acid pool, impaired lipid oxidation, and the development of non-alcoholic fatty liver disease (NAFLD) (Parséus et al., 2017).



Fig. 1. *TGR5-mediated cell signalling pathways in different liver cell types. TGR5 activation leads to increased intracellular cAMP levels, followed by activation of PKA, ultimately leading to altered gene expression [**1**,**2**], resulting in relaxation of gallbladder smooth muscle cells and increased gallbladder filling. TGR5 signalling in Kupffer cells decreases LPS-induced cytokine production via a cAMP-dependent pathway [**20**] and antagonizes NF-κB, both resulting in a decreased hepatic inflammatory response [**15**,**39**]. TGR5 signalling in non-ciliated cholangiocytes inhibits ERK1/2 signalling, resulting in increased proliferation; whereas in ciliated cholangiocytes, TGR5 signalling increases ERK1/2 activity to decrease proliferation [**5**]. TGR5 signalling in liver sinusoidal endothelial cells enhances AKT phosphorylation and increases vasodilation [**45**,**46**]. (Holter et al.,2020)*

3.4 The Gut-Brain Axis: Neuro-Metabolic Signalling

The gut-brain axis represents a bidirectional communication system that integrates intestinal functions with the cognitive and emotional centers of the brain (Cryan & Dinan, 2012). In obesity, this axis is often hijacked by microbial signals that alter appetite, reward-seeking behaviour, and energy expenditure.

3.4.1 Vagal Nerve Signalling

The vagus nerve is the primary neural highway connecting the gut to the brain (Fulling et al., 2019). Enteroendocrine cells (EECs) in the gut lining possess "neuropods"—long cytoplasmic extensions that form physical synapses with vagal afferent fibers (Kaelberer et al., 2018). When microbes produce metabolites like SCFAs or hydrogen sulfide, these cells can transmit a signal to the brainstem within milliseconds, influencing satiety and gastric emptying (Kaelberer et al., 2018).

3.4.2 Hormonal Pathways: GLP-1, PYY, and Ghrelin

Beyond direct neural contact, microbes influence the secretion of "incretin" hormones. *Akkermansia muciniphila*, for instance, produces a protein (Amuc_1100) that interacts with TLR2 to increase the secretion of GLP-1, which suppresses appetite and improves insulin sensitivity (Plovier et al., 2017). Conversely, chronic dysbiosis can lead to "leptin resistance," where the brain no longer receives the signal that fat stores are sufficient, leading to overeating (Queipo-Ortuño et al., 2013).

3.5 The Gut-Endocannabinoid System Axis: A Regulatory Gateway

Recent pharmacological and metagenomic investigations have unveiled a sophisticated bidirectional link between the gut microbiota and the host's endocannabinoid system (eCB), which serves as a master regulator of energy balance, lipogenesis, and gut barrier permeability (Muccioli et al., 2010). The eCB consists of lipid-based neurotransmitters—primarily arachidonoylethanolamide (anandamide, AEA) and 2-arachidonoylglycerol (2-AG)—and their cognate G protein-coupled receptors, CB1 and CB2 (Cani & Jordan, 2018).

3.5.1 Microbial Regulation of eCB Tone

Evidence suggests that gut dysbiosis induced by high-fat diets leads to a systemic and localized overactivation of the eCB (Cani et al., 2012). Specifically, a reduction in the abundance of *Akkermansia muciniphila* and *Lactobacillus* species is correlated with increased expression of CB1 receptors in the intestinal epithelium and adipose tissue (Everard et al., 2013). This "eCB tone" modulation is significant because CB1 activation in the gut increases intestinal permeability by disrupting the localization of zonulin and occludin, thereby facilitating metabolic endotoxemia (Muccioli et al., 2010). Conversely, certain probiotic strains have been shown to upregulate the expression of the enzyme fatty acid amide hydrolase (FAAH), which degrades anandamide, effectively lowering the pro-inflammatory eCB signal and restoring barrier integrity (Cani et al., 2012).

3.5.2 Adipose Tissue Remodelling and "Browning"

The interaction between microbial metabolites and the eCB also extends to the metabolic "programming" of adipose tissue (Muccioli et al., 2010). Activation of the eCB system in white adipose tissue (WAT) promotes adipogenesis and inhibits the thermogenic "browning" of fat cells—a process where white adipocytes take on the mitochondrial characteristics of brown fat (Cani & Jordan, 2018). Microbiota-derived Short-Chain Fatty Acids (SCFAs) have been shown to antagonize this eCB-driven fat accumulation. By suppressing CB1 receptor expression and activating the GPR43/AMPK pathway, SCFAs promote the expression of Uncoupling Protein 1 (UCP1) and PGC-1α, facilitating energy expenditure over lipid storage (Kimura et al., 2013; Cani & Jordan, 2018).

3.5.3 The "Gut-Brain-Adipose" Triangle

The eCB system also acts as a bridge in the gut-brain-adipose triangle, where microbial signals influence central satiety through the modulation of hypothalamic CB1 receptors (Cryan & Dinan, 2012). Dysbiosis-induced elevations in circulating LPS can trigger hypothalamic inflammation, which in turn dysregulates eCB-mediated leptin signalling (Cani et al., 2012). This neuro-endocrine disruption creates a feedback loop where the host experiences increased cravings for high-density caloric foods, further fuelling the dysbiotic state (Postler & Ghosh, 2017). Understanding the microbial-eCB axis offers a novel therapeutic window for "antagonist-like" probiotic interventions that could naturally downregulate eCB overactivation without the psychiatric side effects associated with synthetic CB1 antagonists (Muccioli et al., 2010).

4. Information Systems and Bioinformatics in Microbiome Research

The transition of microbiome research from a descriptive science to a predictive, systems-based discipline has been driven entirely by the evolution of high-throughput sequencing technologies and advanced bioinformatic pipelines (Knight et al., 2018). In the context of metabolic syndrome, the ability to process massive metagenomic datasets allows for the identification of subtle microbial signatures that would be invisible to traditional culturing methods (Quince et al., 2017).

4.1 Next-Generation Sequencing (NGS) Architectures

Two primary strategies dominate the field: 16S rRNA gene sequencing and Shotgun Metagenomic Sequencing (Mirdita et al., 2017). 16S rRNA sequencing targets specific hypervariable regions (usually V3–V4) of the bacterial ribosomal RNA gene, acting as a "molecular barcode" for taxonomic identification (Caporaso et al., 2011). While cost-effective for large-scale epidemiological studies, it lacks the resolution to distinguish between closely related species or to provide functional data (Langille et al., 2013).

In contrast, Shotgun Metagenomics shears all DNA in a sample, providing a comprehensive view of the entire genetic potential of the community (Quince et al., 2017). This allows researchers to perform "functional profiling"—determining not just *who* is there, but *what* they are doing (e.g., measuring the abundance of genes responsible for butyrate production or LPS biosynthesis) (Abubucker et al., 2012).

4.2 Bioinformatic Pipelines and Data Normalization

Processing raw sequencing data requires robust computational infrastructure. Modern pipelines like **QIIME 2** (Quantitative Insights Into Microbial Ecology) and **Mothur** utilize denoising algorithms such as DADA2 or Deblur to resolve Amplicon Sequence Variants (ASVs), which provide higher taxonomic resolution than older Operational Taxonomic Unit (OTU) methods (Callahan et al., 2016). While OTU clustering groups sequences at a 97% similarity threshold, DADA2 models the sequencing error rate to distinguish biological variations from technical noise at the single-nucleotide level (Callahan et al., 2016). This precision is critical in obesity research for identifying specific "keystone" strains that might differ by only a few nucleotides but have vastly different effects on host insulin sensitivity (Knight et al., 2018).

For shotgun data, tools like **HUMAnN 3** (HMP Unified Metabolic Analysis Network) are employed to reconstruct metabolic pathways from fragmented genomic data, mapping reads to the KEGG (Kyoto Encyclopedia of Genes and Genomes) or MetaCyc databases (Franzosa et al., 2018). Normalization is critical here; because sequencing depth varies between samples, bioinformaticians must use compositional data analysis methods to avoid "spurious correlations" in metabolic data (Gloor et al., 2017).

4.3 Machine Learning and Predictive Modeling in Obesity

The "Information Technology" aspect of microbiome research is best exemplified by the application of Machine Learning (ML) to predict metabolic outcomes (Topçuoğlu et al., 2020). The application of Information Technology to the microbiome is not merely about storage; it is about the extraction of predictive features from high-dimensional, sparse datasets (Knight et al., 2018). Beyond taxonomic identification, the use of Random Forest (RF) and Gradient Boosting Machine (GBM) architectures has allowed for the creation of sophisticated diagnostic models. RF classifiers and Support Vector Machines (SVM) are now routinely trained on stool metagenomes to identify individuals at high risk for Type 2 Diabetes. In the study by Zeevi et al. (2015), researchers utilized a cohort of 800 individuals to train a machine learning algorithm that integrates 16S rRNA profiles, blood parameters, and physical activity logs (Zeevi et al., 2015). The Random Forest model, which consists of an ensemble of decision trees, was able to identify non-linear relationships between specific microbial abundances and postprandial glycaemic responses (PPGR) (Zeevi et al., 2015). For instance, the presence of certain *Bacteroidetes* species was found to modulate the host's response to complex carbohydrates, a finding that traditional statistical models like linear regression failed to capture (Zeevi et al., 2015). This computational approach provides the foundation for precision nutrition, where "digital twins" of a patient's gut can be used to simulate the metabolic impact of specific dietary interventions before they are implemented clinically (Topçuoğlu et al., 2020).

Furthermore, the integration of Shotgun Metagenomics allows for the mapping of sequences to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, facilitating a functional rather than just taxonomic analysis (Abubucker et al., 2012). By calculating the "Metabolic Potential" of a community, bioinformaticians can determine if a patient's gut is genetically predisposed to high levels of metabolic endotoxemia by quantifying the abundance of genes involved in Lipopolysaccharide (LPS) biosynthesis (Franzosa et al., 2018). This transition from "who is there" to "what are they doing" is the hallmark of modern systems biology in metabolic research (Hasin et al., 2017).

In the study by Zeevi integrating metagenomic abundance, dietary logs, and physiological parameters, the system achieved high predictive accuracy for postprandial glycaemic responses ($R = 0.68$), significantly outperforming traditional carbohydrate counting (Zeevi et al., 2015)

In a landmark study, Machine Learning models demonstrated that the gut microbiota's response to dietary fibre is highly individualized, allowing for the creation of "Personalized Glycaemic Response" algorithms (Zeevi et al., 2015). These systems integrate microbiome data with blood parameters and wearable-device logs to provide real-time nutritional advice via smartphone applications, representing the pinnacle of systems biology in the life sciences (Postler & Ghosh, 2017).

4.4 Multi-Omics Integration and Network Analysis

To fully understand metabolic syndrome, researchers must integrate metagenomics with **metabolomics** (the study of small molecules like SCFAs and bile acids) and **transcriptomics** (the study of host gene expression) (Hasin et al., 2017). Network analysis tools, such as SPIEC-EASI, allow for the visualization of co-occurrence patterns between specific bacteria and host metabolites (Kurtz et al., 2015). These "inter-kingdom" networks help identify "keystone species"—microbes that exert a disproportionately large influence on the host's metabolic health regardless of their abundance (Banerjee et al., 2018).

5. Therapeutic Perspectives and Clinical Evidence

The realization that the gut microbiota is a plastic and modifiable ecosystem has catalysed a shift toward microbiome-based therapeutics. Unlike genetic predispositions, which are currently immutable, the microbial community offers a "druggable" target for the management of obesity and metabolic syndrome (Cani, 2018). These interventions range from broad dietary modifications to highly targeted "precision biotic" engineering.

5.1 Fecal Microbiota Transplantation (FMT): Lessons from Clinical Trials

Fecal Microbiota Transplantation (FMT) represents the most direct method of microbial modulation, involving the transfer of a complete, functional ecosystem from a healthy donor to a diseased recipient (Borody & Khoruts, 2011). While FMT is the gold standard for treating recurrent *Clostridioides difficile* infections, its application in metabolic disease has yielded complex results.

In the seminal **Amsterdam Study**, lean-donor FMT was administered to subjects with metabolic syndrome via a duodenal tube (Vrieze et al., 2012). Six weeks post-treatment, the recipients showed a significant increase in peripheral insulin sensitivity in males with metabolic syndrome and a notable rise in levels of butyrate-producing bacteria like *Roseburia intestinalis*.

However, the follow-up Kootte et al. (2017) trial revealed a crucial "Metabolic Memory" effect (Kootte et al., 2017). While 50% of recipients were "responders," their insulin sensitivity returned to baseline levels by the 18-week mark (Kootte et al., 2017).

The Kootte study identified that the success of FMT was dictated by two primary factors:

- **Baseline Diversity:** Recipients with the lowest initial microbial gene richness experienced the most significant metabolic shifts (Kootte et al., 2017).
- **Donor-Recipient Compatibility:** Successful engraftment of butyrate-producing *Roseburia intestinalis* was essential for sustained GLP-1 secretion and glucose control (Kootte et al., 2017).

Patients who initially possessed high microbial diversity showed little change, whereas those with low diversity experienced significant metabolic shifts. Furthermore, the "lean" effect was often lost by the 12-week mark, suggesting that host dietary patterns eventually "override" the donor microbiota, necessitating repeated treatments or concomitant dietary fibre supplementation.

This comparison suggests that FMT for metabolic syndrome cannot be a "one-size-fits-all" solution; rather, it requires precision donor matching and post-transplant dietary management to maintain the "lean" microbial phenotype (Maruvada et al., 2017).

5.1.1 Comparative Analysis of FMT: Amsterdam vs. Kootte Protocols

To understand the therapeutic potential of Fecal Microbiota Transplantation (FMT), one must analyse the discrepancies between short-term success and long-term sustainability (Borody & Khoruts, 2011). The seminal Amsterdam Study (Vrieze et al., 2012) provided the first definitive proof that the lean phenotype could be partially transferred to subjects with metabolic syndrome (Vrieze et al., 2012). In this double-blind trial, recipients of lean-donor faeces showed a 176% increase in insulin sensitivity compared to those who received an autologous transplant (Vrieze et al., 2012). This improvement was highly correlated with a significant increase in the abundance of *butyrate-producing* bacteria, which were hypothesized to strengthen the gut barrier and reduce systemic inflammation (Vrieze et al., 2012).

However, the follow-up study by Kootte et al. (2017) introduced the critical concept of the "responder" versus "non-responder" (Kootte et al., 2017). By extending the observation period and increasing the sample size, researchers found that while initial improvements were promising, only about 50% of the participants maintained improved glucose disposal rates after 18 weeks (Kootte et al., 2017). The bioinformatic analysis revealed that "responders" possessed a distinct baseline microbial signature characterized by low initial gene richness (Kootte et al., 2017). This suggests that a "vacant niche" must exist in the recipient's gut for the donor's beneficial microbes, such as *Roseburia intestinalis*, to successfully engraft (Kootte et al., 2017). Furthermore, the study noted that the "metabolic memory" of the host—driven by persistent adipocyte inflammation—tended to revert the microbiota to its original "obese" state if the intervention was not supported by chronic dietary changes (Kootte et al., 2017). These findings underscore the necessity of "Personalized FMT," where donors are selected not just for their health, but for their microbial compatibility with the recipient's specific dysbiotic profile (Maruvada et al., 2017).

5.2 Next-Generation Probiotics (NGPs) and Postbiotics

The traditional probiotic market, dominated by *Lactobacillus* and *Bifidobacterium*, is being superseded by "Next-Generation Probiotics" (NGPs)—strains identified through metagenomic analysis as being specifically relevant to human health.

- **Akkermansia muciniphila:** This species is perhaps the most promising candidate. A double-blind, placebo-controlled pilot study (Depommier et al., 2019) demonstrated that daily oral supplementation of *A. muciniphila* (both live and pasteurized) was safe and well-tolerated. Interestingly, the pasteurized (heat-killed) form resulted in even greater improvements in insulin sensitivity and a reduction in total plasma cholesterol. This introduces the concept of **Postbiotics**: inanimate microorganisms and/or their components that confer a health benefit on the host (Salminen et al., 2021). The efficacy of heat-killed *Akkermansia* is attributed to the **Amuc_1100** protein, which remains stable after heat treatment and continues to interact with the TLR2 receptor, strengthening the gut barrier (Plovier et al., 2017).
- **Christensenella minuta:** Highly heritable and inversely associated with BMI, this species has shown potential in animal models to prevent weight gain by altering the host's lipid metabolism pathways (Goodrich et al., 2014).

5.3 Precision Engineering: CRISPR-Cas9 and Phage Therapy

The journal's focus on Information Technology is particularly relevant in the field of microbiome engineering. We are moving toward a "surgical" approach to the microbiome, where specific harmful genes or strains are eliminated without disrupting the entire community.

- **CRISPR-Cas9 Modulation:** Researchers have successfully used CRISPR-Cas9 delivered via engineered bacteriophages to selectively kill antibiotic-resistant strains of *E. coli* in the gut. In the context of metabolic syndrome, this technology could be used to silence genes responsible for the production of Trimethylamine (TMA), the precursor to the pro-atherogenic molecule TMAO (Wang et al., 2015).
- **Bacteriophage Therapy:** Phages are viruses that infect specific bacteria. By designing "phage cocktails" that target the pro-inflammatory Proteobacteria found in obese patients, clinicians may be able to "reset" the gut environment to a lean state (Gomaa et al., 2014).

5.4 Personalized Nutrition Guided by Information Systems

As discussed in the bioinformatics section, the integration of microbiome data into personalized nutrition is the future of metabolic therapy. The **PREDICT 1 Study** (Berry et al., 2020) demonstrated that the gut microbiome is a better predictor of postprandial triglyceride and glucose levels than any other individual factor, including genetics. Information systems that use Random Forest algorithms to analyse these "multi-omic" datasets are now being deployed in commercial health platforms, allowing users to select foods that minimize their personal inflammatory response (Zeevi et al., 2015).

6. Clinical Evidence in Humans: Longitudinal Cohorts and Metagenomic Signatures

While early research focused on cross-sectional snapshots of the microbiota, recent longitudinal studies have provided deeper insights into how microbial shifts precede the clinical onset of metabolic syndrome (Karlsson et al., 2013). Large-scale metagenomic association studies (MWAS) have identified that the "obese microbiome" is not merely defined by the presence of specific bacteria, but by a significant depletion of genes involved in butyrate production and oxidative stress resistance (Qin et al., 2012).

In the MetaHIT and American Gut Project cohorts, individuals categorized as "low gene count" (LGC) individuals exhibited a more pronounced inflammatory phenotype and greater insulin resistance regardless of their initial Body Mass Index (BMI) (Le Chatelier et al., 2013). This suggests that microbial gene richness is a standalone biomarker for metabolic health. Specifically, the depletion of *Faecalibacterium prausnitzii*, a known anti-inflammatory commensal, has been consistently observed in patients with Type 2 Diabetes (T2D) across diverse geographic populations, from Europe to China (Qin et al., 2012; Karlsson et al., 2013). Furthermore, the enrichment of branched-chain amino acid (BCAA) biosynthetic pathways in the gut has been linked to increased systemic levels of leucine and valine, which are known to impair insulin signalling in skeletal muscle (Pedersen et al., 2016). These clinical findings underscore the transition from simple taxonomic observations to a functional understanding of how microbial metabolites dictate the host's metabolic trajectory (Fan & Pedersen, 2021).

6.1 Dietary Patterns and Microbiota-Mediated Metabolic Health

The interaction between dietary patterns and the gut microbiota is a fundamental determinant of metabolic homeostasis (Sonnenburg & Bäckhed, 2016). The "Western Diet," characterized by high intake of saturated fats and refined sugars, acts as a primary driver of dysbiosis by reducing the abundance of fibre-fermenting species (Cani et al., 2008). In contrast, the Mediterranean Diet (MD), rich in polyphenols and monounsaturated fatty acids, has been shown to promote the growth of *Akkermansia muciniphila* and *Bifidobacterium* (Gibson et al., 2017).

6.2 Fiber Consumption and Ecological Diversity

Dietary fibres serve as Microbiota-Accessible Carbohydrates (MACs). When MAC intake is low, specialized bacteria are forced to forage on the host's mucus layer, leading to increased intestinal permeability and the translocation of LPS into the bloodstream (Cani et al., 2007; Schroeder & Bäckhed, 2016). A high-fibre intervention study demonstrated that specific fibres can selectively promote a group of SCFA-producing strains that act as a functional guild to improve HbA1c levels in diabetic patients (Zhao et al., 2018).

6.3 Polyphenols and Precision Nutrition

Polyphenols found in berries, green tea, and red wine are poorly absorbed in the small intestine and reach the colon, where they are metabolized by the microbiota into bioactive phenolic acids (Valdes et al., 2018). These metabolites have been shown to inhibit the growth of pathogenic *Clostridia* and promote a leaner metabolic phenotype by activating the AMPK pathway in the liver (Cani & Jordan, 2018). The integration of these dietary variables into machine learning models allows for "Precision Nutrition" (Zeevi et al., 2015), where the metabolic impact of a meal is predicted based on the individual's microbial capacity to process specific nutrients (Postler & Ghosh, 2017).

7. Challenges and Future Perspectives

Despite the significant strides made in microbiome research, several formidable challenges remain before microbiota-based therapies can be integrated into standard clinical practice (Cani, 2018).

7.1 The Challenge of Inter-Individual Variability

The "one-size-fits-all" approach to probiotics and dietary advice is increasingly viewed as obsolete (Knight et al., 2018). Research indicates that the host's genetic background and existing microbial "enterotype" significantly influence the success of any intervention (Goodrich et al., 2014). For instance, certain individuals are "non-responders" to fibre supplementation because they lack the primary degraders required to initiate the fermentation cascade (Kootte et al., 2017).

7.2 Standardization of Bioinformatics and Data Integration

The lack of standardized protocols for stool collection, DNA extraction, and bioinformatic processing remains a hurdle (Quince et al., 2017). Different pipelines (e.g., QIIME 2 vs. Mothur) can yield different results from the same sample, complicating the comparison of clinical trials (Callahan et al., 2016). Future research must prioritize the development of "Unified Omics" frameworks that can integrate metagenomic, metabolomic, and proteomic data into a single diagnostic output (Hasin et al., 2017).

7.3 Ethical and Regulatory Frontiers

As we move toward faecal transplants and CRISPR-engineered microbes, the ethical implications of "editing" a person's microbiome must be addressed. Regulatory agencies like the FDA currently lack a clear framework for classifying live biotherapeutic products (LBPs), which slows the transition from experimental trials to pharmaceutical availability (Borody & Khoruts, 2011). Looking forward, the next decade of research will likely focus on the **virome** and **mycobiome**, exploring how viruses and fungi interact with bacteria to regulate our metabolic health (Cani, 2018).

8. Discussion: Ethics, and Global Trends

The integration of the gut microbiota into the clinical management of obesity represents a paradigm shift, yet several hurdles remain.

8.1 The "Responder" vs. "Non-Responder" Phenomenon

One of the most persistent challenges in clinical trials is the high degree of inter-individual variability. Why do some patients lose weight on a Mediterranean diet while others do not? The answer likely lies in "microbial readiness." If a patient lacks the specific bacteria required to ferment complex fibres into butyrate, a high-fibre diet may lead to gastrointestinal distress rather than metabolic improvement (Zhao et al., 2018). This necessitates a move toward **stratified clinical trials**, where participants are grouped by their microbial enterotype before treatment begins.

8.2 Ethical and Regulatory Considerations

The use of FMT and CRISPR-engineered microbes raises significant ethical questions. The long-term safety of transferring an entire ecosystem from one individual to another is still being evaluated, particularly regarding the risk of transferring "hidden" traits like susceptibility to depression or colorectal cancer (Borody & Khoruts, 2011). Furthermore, regulatory bodies like the FDA and EMA are currently struggling to classify these treatments- are they "drugs," "biologics," or "human tissue"?

8.3 The Global Perspective: Westernization vs. Indigenous Microbiomes

As developing nations adopt Western diets, their traditional, high-diversity microbiomes are disappearing (Segata, 2015). This "microbial extinction" is closely correlated with the global rise in metabolic syndrome. Information systems must be used to document and preserve the microbial diversity of non-Western populations, which may hold the key to the "original" human metabolic state.

9. Conclusions and summary table

The gut microbiota is a fundamental mediator of human metabolic health, acting as a bridge between diet, inflammation, and energy homeostasis (Lynch & Pedersen, 2016). While the mechanisms of energy harvest and endotoxemia are well-documented, the high degree of inter-individual variability remains a challenge for standardized clinical guidelines (Knight et al., 2018). We are moving away from broad taxonomic descriptions toward a functional understanding of microbial metabolites and their interaction with host receptors (Sonnenburg & Bäckhed, 2016). Future research must prioritize long-term clinical trials to establish the safety and durability of microbiota-based therapies and explore the role of the virome and mycobiome in metabolic disease (Cani, 2018).

Table 1. Key Clinical Trials Investigating Gut Microbiota Modulation in Obesity and Metabolic Syndrome

Trial Name / Author	Intervention Type	Participants	Duration	Key Metabolic Outcomes & Observations	Reference
Amsterdam Study (Vrieze et al.)	FMT (Lean Donor)	Males with MetS (n=18)	6 Weeks	Significant increase in insulin sensitivity (Rd); increase in butyrate-producing Roseburia intestinalis.	Vrieze et al., 2012
Micro-Obes (NCT01314690)	Dietary Intervention	Overweight/Obese (n=49)	6 Months	Low gene richness associated with higher fat mass and inflammatory markers (hs-CRP).	Le Chatelier et al., 2013
Akkermansia Trial (Depommier et al.)	Next-Gen Probiotic (A. muciniphila)	Overweight/Obese (n=32)	3 Months	Pasteurized strain significantly reduced insulin resistance (HOMA-IR) and plasma total cholesterol.	Depommier et al., 2019

Trial Name / Author	Intervention Type	Participants	Duration	Key Metabolic Outcomes & Observations	Reference
B420 Probiotic (Stenman et al.)	Synbiotic (B. lactis + Polydextrose)	Overweight Adults (n=225)	6 Months	Significant reduction in body fat mass and waist circumference; improved gut barrier function.	Stenman et al., 2016
FMT-Memory (Kootte et al.)	FMT (Lean Donor)	Males with MetS (n=38)	18 Weeks	Improvement in insulin sensitivity was transient; baseline microbial diversity predicted response.	Kootte et al., 2017
PREDICT 1 (Berry et al.)	Personalized Nutrition	Large Cohort (n=1,102)	2 Weeks	Microbiome confirmed as a better predictor of postprandial glucose/lipids than genetics.	Berry et al., 2020
FMT Obesity (Mocanu et al.)	FMT (Oral Capsules)	Obese Adults (n=20)	12 Weeks	Increased GLP-1 secretion and shift toward SCFA-producing taxa; modest weight loss.	Mocanu et al., 2021
Fiber-T2D (Zhao et al.)	Prebiotic (High-fiber diet)	Type 2 Diabetes (n=43)	12 Weeks	Selective promotion of acetate/butyrate producers; significant reduction in HbA1c levels.	Zhao et al., 2018
MATOMS Trial (NCT04451148)	Observational/ Metabolic	Pediatric Obese (n=60)	Cross-sectional	Identified specific butyrate-depletion signatures linked to early-onset MetS.	Ongoing (2024-2026)

10. Ethical Considerations & Conflicts of Interest

Ethical Considerations: This manuscript is a literature review and did not involve original research on human or animal subjects by the authors. All primary studies cited herein were conducted under the ethical approval of their respective institutional review boards.

Conflicts of Interest: The authors declare that there are no conflicts of interest regarding the publication of this paper.

Author's contribution:

Conceptualisation and project administration: Karolina Wymoczył

Methodology: Aleksandra Cyrkler and Natalia Cieślak

Validation: Eliza Rajca, Karol Dąbek and Urszula Marzec

Formal analysis and investigation: Agnieszka Giza and Paulina Giza

Resources: Agata Chodkowska

Data curation: Karolina Wymoczył

Writing - original draft, review & editing: Karolina Wymoczył, Agata Chodkowska, Natalia Cieślak, Karol Dąbek, Kamila Czyżak, Eliza Rajca, Agnieszka Giza, Paulina Giza, Urszula Marzec, Aleksandra Cyrkler

Visualisation and supervision: Kamila Czyżak and Karolina Wymoczył

All authors have read and agreed with the published version of the manuscript.

Funding Statement: The study did not receive special funding.

Conflict of Interest Statement: The authors declare no conflict of interest.

Declaration of the use of generative AI and AI-assisted technologies in the writing process: In preparing this work, the authors used ChatGPT for the purpose of improving language, grammar correction, text formatting. After using this tool, the authors reviewed and edited the text as needed and accept full responsibility for the substantive content of the publication.

REFERENCES

1. Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P., Loria, C. M., Smith, S. C., Jr., International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, & International Association for the Study of Obesity. (2009). Harmonizing the metabolic syndrome: A joint interim statement. *Circulation, 120*(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
2. Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004). The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National Academy of Sciences of the United States of America, 101*(44), 15718–15723. https://doi.org/10.1073/pnas.0407076101
3. Borody, T. J., & Khoruts, A. (2011). Fecal microbiota transplantation and emerging applications. *Nature Reviews Gastroenterology & Hepatology, 9*(2), 88–96. https://doi.org/10.1038/nrgastro.2011.244
4. Bouter, K. E., van Raalte, D. H., Groen, A. K., & Nieuwdorp, M. (2017). Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. *Gastroenterology, 152*(7), 1671–1678. https://doi.org/10.1053/j.gastro.2016.12.048
5. Cani, P. D., & Jordan, B. F. (2018). Gut microbiota-mediated inflammation in obesity: A link with gastrointestinal cancer. *Nature Reviews Gastroenterology & Hepatology, 15*(11), 671–682. https://doi.org/10.1038/s41575-018-0025-6
6. Cani, P. D. (2018). Human gut microbiome: Hopes, threats and promises. *Gut, 67*(9), 1716–1725. https://doi.org/10.1136/gutjnl-2018-316723
7. Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., Waget, A., Delmée, E., Cousin, B., Sulpice, T., Chamontin, B., Ferrières, J., Tanti, J. F., Gibson, G. R., Casteilla, L., Delzenne, N. M., … Burcelin, R. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes, 56*(7), 1761–1772. https://doi.org/10.2337/db06-1491
8. Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes, 57*(6), 1470–1481. https://doi.org/10.2337/db07-1403
9. Cani, P. D., Osto, M., Geurts, L., & Everard, A. (2012). Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. *Gut Microbes, 3*(4), 279–288. https://doi.org/10.4161/gmic.19625
10. Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience, 13*(10), 701–712. https://doi.org/10.1038/nrn3346
11. Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., de Barsy, M., Loumaye, A., Hermans, M. P., Thissen, J. P., de Vos, W. M., & Cani, P. D. (2019). Supplementation with *Akkermansia muciniphila* in overweight and obese human volunteers: A proof-of-concept exploratory study. *Nature Medicine, 25*(7), 1096–1103. https://doi.org/10.1038/s41591-019-0495-2
12. Evans, J. M., Morris, L. S., & Marchesi, J. R. (2013). The gut microbiome: The role of a virtual organ in the endocrinology of the host. *The Journal of Endocrinology, 218*(3), R37–R47. https://doi.org/10.1530/JOE-13-0131
13. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., de Vos, W. M., & Cani, P. D. (2013). Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proceedings of the National Academy of Sciences of the United States of America, 110*(22), 9066–9071. https://doi.org/10.1073/pnas.1219451110
14. Frost, G., Sleeth, M. L., Sahuri-Arisoylu, M., Lizarbe, B., Cerdan, S., Brody, L., Anastasovska, J., Ghourab, S., Hankir, M., Zhang, S., Carling, D., Swann, J. R., Gibson, G., Viardot, A., Morrison, D., Louise Thomas, E., & Bell, J. D. (2014). The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. *Nature Communications, 5*, 3611. https://doi.org/10.1038/ncomms4611
15. Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., Verbeke, K., & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics. *Nature Reviews Gastroenterology & Hepatology, 14*(8), 491–502. https://doi.org/10.1038/nrgastro.2017.75
16. Hotamisligil, G. S. (2006). Inflammation and metabolic disorders. *Nature, 444*(7121), 860–867. https://doi.org/10.1038/nature05485
17. Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013). Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature, 498*(7452), 99–103. https://doi.org/10.1038/nature12198
18. Knight, R., Vrbanac, A., Taylor, B. C., Aksenov, A., Callewaert, C., Debelius, J., Gonzalez, A., Kosciolek, T., McCall, L. I., McDonald, D., Melnik, A. V., Morton, J. T., Navas, J., Quinn, R. A., Sanders, J. G., Swafford, A. D., Thompson, L. R., Tripathi, A., Xu, Z. Z., Zaneveld, J. R., … Dorrestein, P. C. (2018). Best practices for analysing microbiomes. *Nature Reviews Microbiology, 16*(7), 410–422. https://doi.org/10.1038/s41579-018-0029-9

19. Kootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., Hermes, G., Bouter, K. E., Koopen, A. M., Holst, J. J., Knop, F. K., Blaak, E. E., Zhao, J., Smidt, H., Harms, A. C., Hankemeijer, T., Bergman, J. J. G. H. M., Romijn, H. A., Schaap, F. G., Olde Damink, S. W. M., … Nieuwdorp, M. (2017). Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell Metabolism, 26*(4), 611–619.e6. https://doi.org/10.1016/j.cmet.2017.09.008
20. Chow, M. D., Lee, Y. H., & Guo, G. L. (2017). The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Molecular Aspects of Medicine, 56*, 34–44. https://doi.org/10.1016/j.mam.2017.04.004
21. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J. M., Kennedy, S., Leonard, P., Li, J., Burgdorf, K., Grarup, N., Jørgensen, T., Brandslund, I., Nielsen, H. B., Juncker, A. S., Bertalan, M., Levenez, F., … Pedersen, O. (2013). Richness of human gut microbiome correlates with metabolic markers. *Nature, 500*(7464), 541–546. https://doi.org/10.1038/nature12506
22. Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005). Obesity alters gut microbial ecology. *Proceedings of the National Academy of Sciences of the United States of America, 102*(31), 11070–11075. https://doi.org/10.1073/pnas.0504978102
23. Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006). Microbial ecology: Human gut microbes associated with obesity. *Nature, 444*(7122), 1022–1023. https://doi.org/10.1038/4441022a
24. Lin, H. V., Frassetto, A., Kowalik, E. J., Jr., Nawrocki, A. R., Lu, M. M., Kosinski, J. R., Hubert, J. A., Szeto, D., Yao, X., Forrest, G., & Marsh, D. J. (2012). Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLOS ONE, 7*(4), e35240. https://doi.org/10.1371/journal.pone.0035240
25. Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. *The New England Journal of Medicine, 375*(24), 2369–2379. https://doi.org/10.1056/NEJMra1600266
26. Morrison, D. J., & Preston, T. (2016). Formation of short-chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes, 7*(3), 189–200. https://doi.org/10.1080/19490976.2015.1134082
27. Postler, T. S., & Ghosh, S. (2017). Understanding the holobiont: How microbial metabolites affect human health and shape the immune system. *Cell Metabolism, 26*(1), 110–130. https://doi.org/10.1016/j.cmet.2017.05.008
28. Pussinen, P. J., Havulinna, A. S., Lehto, M., Sundvall, J., & Salomaa, V. (2011). Endotoxemia is associated with an increased risk of incident diabetes. *Diabetes Care, 34*(2), 392–397. https://doi.org/10.2337/dc10-1676
29. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., Peng, Y., Zhang, D., Jie, Z., Wu, W., Qin, Y., Xue, W., Li, J., Han, L., Lu, D., Wu, P., … Wang, J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature, 490*(7418), 55–60. https://doi.org/10.1038/nature11450
30. Queipo-Ortuño, M. I., Seoane, L. M., Murri, M., Pardo, M., Gomez-Zumaquero, J. M., Cardona, F., Casanueva, F., & Tinahones, F. J. (2013). Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. *PLOS ONE, 8*(5), e65465. https://doi.org/10.1371/journal.pone.0065465
31. Byrne, C. S., Chambers, E. S., Morrison, D. J., & Frost, G. (2015). The role of short-chain fatty acids in appetite regulation and energy homeostasis. *International Journal of Obesity, 39*(9), 1331–1338. https://doi.org/10.1038/ijo.2015.84
32. Sanchez, M., Darimont, C., Drapeau, V., Emady-Azar, S., Lepage, M., Rezzonico, E., Ngom-Bru, C., Berger, B., Philippe, L., Ammon-Zuffrey, C., Leone, P., Chevrier, G., St-Amand, E., Marette, A., Doré, J., & Tremblay, A. (2014). Effect of *Lactobacillus rhamnosus* CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. *The British Journal of Nutrition, 111*(8), 1507–1519. https://doi.org/10.1017/S0007114513003875
33. Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H. U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013). Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metabolism, 17*(2), 225–235. https://doi.org/10.1016/j.cmet.2013.01.003
34. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. *The Journal of Clinical Investigation, 116*(11), 3015–3025. https://doi.org/10.1172/JCI28898
35. Sze, M. A., & Schloss, P. D. (2016). Looking for a signal in the noise: Revisiting obesity and the microbiome. *mBio, 7*(4), e01018-16. https://doi.org/10.1128/mBio.01018-16
36. Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., Pellicciari, R., Auwerx, J., & Schoonjans, K. (2009). TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metabolism, 10*(3), 167–177. https://doi.org/10.1016/j.cmet.2009.08.001
37. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature, 444*(7122), 1027–1031. https://doi.org/10.1038/nature05414

38. Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., Egholm, M., Henrissat, B., Heath, A. C., Knight, R., & Gordon, J. I. (2009). A core gut microbiome in obese and lean twins. *Nature, 457*(7228), 480–484. https://doi.org/10.1038/nature07540
39. Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F., Dallinga-Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., Derrien, M., Druesne, A., Van Hylckama Vlieg, J. E., Bloks, V. W., Groen, A. K., Heilig, H. G., Zoetendal, E. G., Stroes, E. S., de Vos, W. M., Hoekstra, J. B., … Nieuwdorp, M. (2012). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology, 143*(4), 913–916.e7. https://doi.org/10.1053/j.gastro.2012.06.031
40. Wahlström, A., Sayin, S. I., Marschall, H. U., & Bäckhed, F. (2016). Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. *Cell Metabolism, 24*(1), 41–50. https://doi.org/10.1016/j.cmet.2016.05.005
41. Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., Ben-Yacov, O., Lador, D., Avnit-Sagi, T., Lotan-Pompan, M., Suez, J., Mahdi, J. A., Matot, E., Malka, G., Kosower, N., Rein, M., Zilberman-Schapira, G., Dohnalová, L., Pevsner-Fischer, M., Bikovsky, R., … Segal, E. (2015). Personalized nutrition by prediction of glycemic responses. *Cell, 163*(5), 1079–1094. https://doi.org/10.1016/j.cell.2015.11.001
42. World Health Organization. (2024, March 1). *Obesity and overweight*. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
43. Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., Muehlbauer, M. J., Ilkayeva, O., Semenkovich, C. F., Funai, K., Hayashi, D. K., Lyle, B. J., Martini, M. C., Ursell, L. K., Clemente, J. C., Van Treuren, W., … Gordon, J. I. (2013). Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science, 341*(6150), 1241214. https://doi.org/10.1126/science.1241214
44. Sonnenburg, J. L., & Bäckhed, F. (2016). Diet-microbiota interactions as moderators of human metabolism. *Nature, 535*(7610), 56–64. https://doi.org/10.1038/nature18846
45. Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y. Y., Wang, X., Fu, H., Xue, X., Lu, C., Ma, J., Yu, L., Xu, C., Ren, Z., Xu, Y., Xu, S., Shen, H., Zhu, X., Shi, Y., Shen, Q., Dong, W., … Zhang, C. (2018). Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science, 359*(6380), 1151–1156. https://doi.org/10.1126/science.aao5774
46. Tremaroli, V., & Bäckhed, F. (2012). Functional interactions between the gut microbiota and host metabolism. *Nature, 489*(7415), 242–249. https://doi.org/10.1038/nature11552
47. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell, 165*(6), 1332–1345. https://doi.org/10.1016/j.cell.2016.05.041
48. Mithieux, G. (2018). Gut microbiota and host metabolism: What relationship. *Neuroendocrinology, 106*(4), 352–356. https://doi.org/10.1159/000484526
49. Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. *Nature Reviews Microbiology, 19*(1), 55–71. https://doi.org/10.1038/s41579-020-0433-9
50. Maruvada, P., Leone, V., Kaplan, L. M., & Chang, E. B. (2017). The human microbiome and obesity: Moving beyond associations. *Cell Host & Microbe, 22*(5), 589–599. https://doi.org/10.1016/j.chom.2017.10.005
51. Schroeder, B. O., & Bäckhed, F. (2016). Signals from the gut microbiota to distant organs in physiology and disease. *Nature Medicine, 22*(10), 1079–1089. https://doi.org/10.1038/nm.4185
52. Valdes, A. M., Walter, J., Segal, E., & Spector, T. D. (2018). Role of the gut microbiota in nutrition and health. *BMJ, 361*, k2179. https://doi.org/10.1136/bmj.k2179
53. Aguilar-Toalá, J. E., García-Varela, R., Garcia, H. S., Mata-Haro, V., González-Córdova, A. F., Vallejo-Cordoba, B., & Hernandez-Mendoza, A. (2018). Postbiotics: An evolving term within the functional foods field. *Trends in Food Science & Technology, 75*, 105–114. https://doi.org/10.1016/j.tifs.2018.03.009
54. Bjursell, M., Admyre, T., Göransson, M., Marley, A. E., Smith, D. M., Oscarsson, J., & Bohlooly-Y, M. (2011). Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. *American Journal of Physiology-Endocrinology and Metabolism, 300*(1), E211–E220. https://doi.org/10.1152/ajpendo.00229.2010
55. Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., Pike, N. B., Strum, J. C., Steplewski, K. M., Murdock, P. R., Holder, J. C., Marshall, F. H., Szekeres, P. G., Wilson, S., Ignar, D. M., Foord, S. M., … Dowell, S. J. (2003). The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *The Journal of Biological Chemistry, 278*(13), 11312–11319. https://doi.org/10.1074/jbc.M211609200
56. Zimmerman, M. A., Singh, N., Martin, P. M., Thangaraju, M., Ganapathy, V., Waller, J. L., Shi, H., Robertson, K. D., Munn, D. H., & Liu, K. (2012). Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. *American Journal of Physiology-Gastrointestinal and Liver Physiology, 302*(12), G1405–G1415. https://doi.org/10.1152/ajpgi.00543.2011

57. De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., Bäckhed, F., & Mithieux, G. (2014). Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. *Cell, 156*(1–2), 84–96. https://doi.org/10.1016/j.cell.2013.12.016
58. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N. N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., Clarke, J. M., … Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature, 504*(7480), 446–450. https://doi.org/10.1038/nature12721
59. Ge, H., Li, X., Weiszmann, J., Wang, P., Baribault, H., Chen, J. L., Tian, H., & Li, Y. (2008). Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. *Endocrinology, 149*(9), 4519–4526. https://doi.org/10.1210/en.2008-0059
60. Gomaa, A. A., Klumpe, H. E., Luo, M. L., Selle, K., Barrangou, R., & Beisel, C. L. (2014). Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. *mBio, 5*(1), e00928-13. https://doi.org/10.1128/mBio.00928-13
61. Kalliomäki, M., Collado, M. C., Salminen, S., & Isolauri, E. (2008). Early differences in fecal microbiota composition in children may predict overweight. *The American Journal of Clinical Nutrition, 87*(3), 534–538. https://doi.org/10.1093/ajcn/87.3.534
62. Kimura, I., Inoue, D., Maeda, T., Hara, T., Ichimura, A., Miyauchi, S., Kobayashi, M., Hirasawa, A., & Tsujimoto, G. (2011). Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41. *Proceedings of the National Academy of Sciences of the United States of America, 108*(19), 8030–8035. https://doi.org/10.1073/pnas.1016088108
63. Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., Terasawa, K., Kashihara, D., Hirano, K., Tani, T., Takahashi, T., Miyauchi, S., Shioi, G., Inoue, H., & Tsujimoto, G. (2013). The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nature Communications, 4*, 1829. https://doi.org/10.1038/ncomms2852
64. Macfarlane, G. T., & Macfarlane, S. (2011). Fermentation in the human large intestine: Its physiologic consequences and the potential contribution of prebiotics. *Journal of Clinical Gastroenterology, 45*(Suppl.), S120–S127. https://doi.org/10.1097/MCG.0b013e31822fecfe
65. Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., Myridakis, A., Delzenne, N. M., Klievink, J., Bhattacharjee, A., van der Ark, K. C., Aalvink, S., Martinez, L. O., Dumas, M. E., Maiter, D., Loumaye, A., … Cani, P. D. (2017). A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nature Medicine, 23*(1), 107–113. https://doi.org/10.1038/nm.4236
66. Samuel, B. S., Shaito, A., Motoike, T., Rey, F. E., Backhed, F., Manchester, J. K., Hammer, R. E., Williams, S. C., Crowley, J., Yanagisawa, M., & Gordon, J. I. (2008). Effects of the gut microbiota on host adiposity are modulated by the short-chain-fatty-acid binding G protein-coupled receptor Gpr41. *Proceedings of the National Academy of Sciences of the United States of America, 105*(43), 16767–16772. https://doi.org/10.1073/pnas.0808567105
67. Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., Lee, J. R., Offermanns, S., & Ganapathy, V. (2014). Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity, 40*(1), 128–139. https://doi.org/10.1016/j.immuni.2013.12.007
68. Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science, 341*(6145), 569–573. https://doi.org/10.1126/science.1241165
69. Thaiss, C. A., Itav, S., Rothschild, D., Meijer, M. T., Levy, M., Moresi, C., Dohnalová, L., Braverman, S., Rozin, S., Malitsky, S., Dori-Bachash, M., Kuperman, Y., Biton, I., Gertler, A., Harmelin, A., Shapiro, H., Halpern, Z., Aharoni, A., Segal, E., & Elinav, E. (2016). Persistent microbiome alterations modulate the rate of post-dieting weight regain. *Nature, 540*(7634), 544–551. https://doi.org/10.1038/nature20796
70. Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012). Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes, 61*(2), 364–371. https://doi.org/10.2337/db11-1019
71. Ghoshal, S., Witta, J., Zhong, J., de Villiers, W., & Eckhardt, E. (2009). Chylomicrons promote intestinal absorption of lipopolysaccharides. *Journal of Lipid Research, 50*(1), 90–97. https://doi.org/10.1194/jlr.M800156-JLR200
72. Groschwitz, K. R., & Hogan, S. P. (2009). Intestinal barrier function: Molecular regulation and disease pathogenesis. *The Journal of Allergy and Clinical Immunology, 124*(1), 3–22. https://doi.org/10.1016/j.jaci.2009.05.038
73. Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996). IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. *Science, 271*(5249), 665–668. https://doi.org/10.1126/science.271.5249.665
74. Muccioli, G. G., Naslain, D., Bäckhed, F., Reigstad, C. S., Lambert, D. M., Delzenne, N. M., & Cani, P. D. (2010). The endocannabinoid system links gut microbiota to adipogenesis. *Molecular Systems Biology, 6*, 392. https://doi.org/10.1038/msb.2010.46

75. Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., Le Chatelier, E., Levenez, F., Doré, J., Mattila, I., Plichta, D. R., Pöhö, P., Hellgren, L. I., Arumugam, M., Sunagawa, S., Vieira-Silva, S., … Pedersen, O. (2016). Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature, 535*(7612), 376–381. https://doi.org/10.1038/nature18646
76. Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. *The Journal of Clinical Investigation, 116*(11), 3015–3025. https://doi.org/10.1172/JCI28898
77. Stenman, L. K., Lehtinen, M. J., Meland, N., Christensen, J. E., Yeung, N., Saarinen, M. T., Courtney, M., Burcelin, R., Lähdeaho, M. L., Linros, J., Apter, D., Scheinin, M., Kloster Smerud, H., Rissanen, A., & Lahtinen, S. (2016). Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults: Randomized controlled trial. *EBioMedicine, 13*, 190–200. https://doi.org/10.1016/j.ebiom.2016.10.036
78. Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., & Chen, H. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *The Journal of Clinical Investigation, 112*(12), 1821–1830. https://doi.org/10.1172/JCI19451
79. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. *The Journal of Clinical Investigation, 112*(12), 1796–1808. https://doi.org/10.1172/JCI19246
80. Broeders, E. P., Nascimento, E. B., Havekes, B., Brans, B., Roumans, K. H., Tailleux, A., Schaart, G., Kouach, M., Charton, J., Deprez, B., Bouvy, N. D., Mottaghy, F., Staels, B., van Marken Lichtenbelt, W. D., & Schrauwen, P. (2015). The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. *Cell Metabolism, 22*(3), 418–426. https://doi.org/10.1016/j.cmet.2015.07.002
81. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., Gerard, R. D., Repa, J. J., Mangelsdorf, D. J., & Kliewer, S. A. (2005). Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metabolism, 2*(4), 217–225. https://doi.org/10.1016/j.cmet.2005.09.001
82. Jones, B. V., Begley, M., Hill, C., Gahan, C. G., & Marchesi, J. R. (2008). Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. *Proceedings of the National Academy of Sciences of the United States of America, 105*(36), 13580–13585. https://doi.org/10.1073/pnas.0804437105
83. Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999). Identification of a nuclear receptor for bile acids. *Science, 284*(5418), 1362–1365. https://doi.org/10.1126/science.284.5418.1362
84. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., & Tanaka, K. (2002). Identification of membrane-type receptor for bile acids. *Biochemical and Biophysical Research Communications, 298*(5), 714–719. https://doi.org/10.1016/s0006-291x(02)02550-0
85. Parséus, A., Sommer, N., Sommer, F., Caesar, R., Molinaro, A., Ståhlman, M., Greiner, T. U., Perkins, R., & Bäckhed, F. (2017). Microbiota-induced obesity requires farnesoid X receptor. *Gut, 66*(3), 429–437. https://doi.org/10.1136/gutjnl-2015-310283
86. Ridlon, J. M., Kang, D. J., & Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. *Journal of Lipid Research, 47*(2), 241–259. https://doi.org/10.1194/jlr.R500013-JLR200
87. Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., Schoonjans, K., Bianco, A. C., & Auwerx, J. (2006). Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature, 439*(7075), 484–489. https://doi.org/10.1038/nature04330
88. Abubucker, S., Segata, N., Goll, J., Schubert, A. M., Izard, J., Cantarel, B. L., Rodriguez-Mueller, B., Zucker, J., Thiagarajan, M., Henrissat, B., White, O., Kelley, S. T., Methé, B., Schloss, P. D., Gevers, D., Mitreva, M., & Huttenhower, C. (2012). Metabolic reconstruction for metagenomic data and its application to the human microbiome. *PLOS Computational Biology, 8*(6), e1002358. https://doi.org/10.1371/journal.pcbi.1002358
89. Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J., & Holmes, S. P. (2016). DADA2: High-resolution sample inference from Illumina amplicon data. *Nature Methods, 13*(7), 581–583. https://doi.org/10.1038/nmeth.3869
90. Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Lozupone, C. A., Turnbaugh, P. J., Fierer, N., & Knight, R. (2011). Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proceedings of the National Academy of Sciences of the United States of America, 108*(Suppl. 1), 4516–4522. https://doi.org/10.1073/pnas.1000080107
91. Franzosa, E. A., McIver, L. J., Rahnavard, G., Thompson, L. R., Schirmer, M., Weingart, G., Lipson, K. S., Knight, R., Caporaso, J. G., Segata, N., & Huttenhower, C. (2018). Species-level functional profiling of metagenomes and metatranscriptomes. *Nature Methods, 15*(11), 962–968. https://doi.org/10.1038/s41592-018-0176-y
92. Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V., & Egozcue, J. J. (2017). Microbiome datasets are compositional: And this is not optional. *Frontiers in Microbiology, 8*, 2224. https://doi.org/10.3389/fmicb.2017.02224

93. Hasin, Y., Seldin, M., & Lusis, A. (2017). Multi-omics approaches to disease. *Genome Biology, 18*(1), 83. https://doi.org/10.1186/s13059-017-1215-1
94. Kaelberer, M. M., Buchanan, K. L., Klein, M. E., Barth, B. B., Montoya, M. M., Shen, X., & Bohórquez, D. V. (2018). A gut-brain neural circuit for nutrient sensory transduction. *Science, 361*(6408), eaat5236. https://doi.org/10.1126/science.aat5236
95. Kurtz, Z. D., Müller, C. L., Miraldi, E. R., Littman, D. R., Blaser, M. J., & Bonneau, R. A. (2015). Sparse and compositionally robust inference of microbial ecological networks. *PLOS Computational Biology, 11*(5), e1004226. https://doi.org/10.1371/journal.pcbi.1004226
96. Quince, C., Walker, A. W., Simpson, J. T., Loman, N. J., & Segata, N. (2017). Shotgun metagenomics, from sampling to analysis. *Nature Biotechnology, 35*(9), 833–844. https://doi.org/10.1038/nbt.3935
97. Topçuoğlu, B. D., Lesniak, N. A., Ruffin, M. T., 4th, Wiens, J., & Schloss, P. D. (2020). A framework for effective application of machine learning to microbiome-based classification problems. *mBio, 11*(3), e00434-20. https://doi.org/10.1128/mBio.00434-20
98. Berry, S. E., Valdes, A. M., Drew, D. A., Asnicar, F., Mazidi, M., Wolf, J., Capdevila, J., Hadjigeorgiou, G., Davies, R., Al Khatib, H., Bonnett, C., Ganesh, S., Bakker, E., Hart, D., Mangino, M., Merino, J., Linenberg, I., Wyatt, P., Ordovas, J. M., Gardner, C. D., … Spector, T. D. (2020). Human postprandial responses to food and potential for precision nutrition. *Nature Medicine, 26*(6), 964–973. https://doi.org/10.1038/s41591-020-0934-0
99. Borody, T. J., & Khoruts, A. (2011). Fecal microbiota transplantation and emerging applications. *Nature Reviews Gastroenterology & Hepatology, 9*(2), 88–96. https://doi.org/10.1038/nrgastro.2011.244
100. Goodrich, J. K., Waters, J. L., Poole, A. C., Sutter, J. L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J. T., Spector, T. D., Clark, A. G., & Ley, R. E. (2014). Human genetics shape the gut microbiome. *Cell, 159*(4), 789–799. https://doi.org/10.1016/j.cell.2014.09.053
101. Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., & Vinderola, G. (2021). The International Scientific Association of Probiotics and Prebiotics consensus statement on the definition and scope of postbiotics. *Nature Reviews Gastroenterology & Hepatology, 18*(9), 649–667. https://doi.org/10.1038/s41575-021-00440-6
102. Segata, N. (2015). Gut microbiome: Westernization and the disappearance of intestinal diversity. *Current Biology, 25*(14), R611–R613. https://doi.org/10.1016/j.cub.2015.05.040
103. Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., DiDonato, A. J., Fu, X., Hazen, J. E., Krajcik, D., DiDonato, J. A., Lusis, A. J., & Hazen, S. L. (2015). Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. *Cell, 163*(7), 1585–1595. https://doi.org/10.1016/j.cell.2015.11.055
104. Zhao, L., Zhang, F., Ding, X., Wu, G., Lam, Y. Y., Wang, X., Fu, H., Xue, X., Lu, C., Ma, J., Yu, L., Xu, C., Ren, Z., Xu, Y., Xu, S., Shen, H., Zhu, X., Shi, Y., Shen, Q., Dong, W., … Zhang, C. (2018). Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science, 359*(6380), 1151–1156. https://doi.org/10.1126/science.aao5774
105. Fogelson, K. A., Dorrestein, P. C., Zarrinpar, A., & Knight, R. (2023). The gut microbial bile acid modulation and its relevance to digestive health and diseases. *Gastroenterology, 164*(7), 1069–1085. https://doi.org/10.1053/j.gastro.2023.02.022